NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 01/11/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the reasons why people have gravitated toward benchmark cryptocurrencies is that their supply tends to be deflationary. That is, despite ravenous demand for popular cryptos, their supply — controlled by a dece...

2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and ...

NeuroBo Pharmaceuticals is advancing novel disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The Company has four candidates in the development pipeline, with the lead candidate ANA001 being advanced for treatment of moderate COVID-19. The Company ...

NeuroBo Pharmaceuticals (NASDAQ:NRBO): Q3 GAAP EPS of -$0.16 beats by $0.02. Cash and cash equivalents of $7M Press Release For further details see: NeuroBo Pharmaceuticals EPS beats by $0.02

NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results PR Newswire BOSTON , Nov. 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal d...

NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer Industry Leader Brings More than 30 Years of Pharmaceutical, CRO and Entrepreneurial Experience PR Newswire BOSTON , Nov. 4, 2021 /PRNewswire/ -- NeuroBo Pharmaceutica...

3 Hot Penny Stocks to Add to Your October Watchlist Investing in penny stocks in 2021 has not been easy. And with no signs of easing on volatility anytime soon, investors should be constantly adjusting their strategies. With penny stocks , we tend to see speculation play a much larg...

Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NeuroBo Pharmaceuticals, Inc. Announces Positive Recommendation from Independent Data Safety Monitoring Committee” NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) c...

Gainers: Jasper (NASDAQ:JSPR) +127%. Waitr Holdings (NASDAQ:WTRH) +55%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +46%. Sono-Tek (NASDAQ:SOTK) +26%. Paltalk (NASDAQ:PALT) +21%. Statera Biopharma (NASDAQ:STAB) +20%. SMART Global Holdings (NASDAQ:SGH) +15%. NeuroBo Pharmaceuticals (NASDAQ:NRBO...